Dr. Reddy's Laboratories Ltd. announced the launching of Amoxicillin Tablets Capsules and Oral Suspension, a bio-equivalent generic version of Amoxil (Amoxicillin) Tablets, Capsules and Oral Suspension in the US market on September 17.
The company said Amoxicillin tablets (500 mg and 875 mg), capsules (250 mg and 500 mg) and Oral Suspension (125 mg/5 ml, 200mg/5 ml, 250 mg/5 ml, and 400mg/5 ml) were approved by the US FDA.
The company's Amoxicillin tablets in 500 mg and 875 mg are available in bottle counts of 20 and 100, while Amoxicillin Capsules in 250 mg and 500 mg are available in bottle counts of 100 and 500. Oral Suspension in 200 mg/5 ml and 400 mg/5 ml are available in bottle sizes of 50 ml, 75 ml and 100 ml. Amoxicillin Oral Suspension in 125 mg/5 ml and 250 mg/5 ml are available in bottle sizes of 80 ml, 100 ml, 150 ml.
As per IMS health data, Amoxil brand and generic tables (875 mg) had sales of around $22. 2 million, Capsules had around $67.2 million and Oral Suspension at around $89.5 million in the US market for the twelve months ended June 2012.
At the BSE, Dr. Reddy's Laboratories shares are currently trading at Rs.1,665.30, down 0.66 percent from the previous close.
 | | To receive FREE breaking news email alerts for Dr. Reddy's Laboratories Ltd. and others in your portfolio |
|
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
Business News